glp-1 agonist cardiovascular outcomes receptor versus DPP-4 inhibitor and kidney and in clinical practice in type-2 diabetes Cardiovascular and mortality outcomes with

Animal studies have also shown that portal vein GLP-1 weakens intestinal fat absorption and chylomicron production through the vagal enteric-brain-liver axis, and reduces postprandish and fasting blood lipids [79]

10.1186/1471-2202-13-33 [DOI] [PMC free article] [PubMed] [Google Scholar] Irwin M

Many of these drugs feature novel mechanisms of action or routes of administration and this increased competition may eventually exert downward pressure on pricing

Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials

For people already using a closed-loop system, that is a meaningful step forward

Patients typically begin with a low dose usually 0.25 mg of semaglutide and increase the dosage every four weeks